The Company expects a decrease in cash, cash equivalents, and investments of approximately $190 million in 2024. Based on current assumptions, the Company continues to expect its cash runway to fund operations into 2026. GAAP Operating Expenses are expected to be approximately $280 million, including estimated non-cash stock-based compensation expense of approximately $60 million. These estimates exclude any impact from potential business development activities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene, Arbor enter global gene editing license agreement
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Allogene Therapeutics management to meet with Truist
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
